Clinical Report: Investigation of Intravenous L-arginine on Lactate Metabolism
Overview
This study demonstrates that intravenous L-arginine significantly reduces lactate levels in brain metastases, with the most pronounced effect observed at a 30 g dose approximately 30 minutes post-infusion. The findings suggest a potential role for L-arginine as a radiosensitizer in future clinical trials.
Background
Brain metastases are a common and challenging complication of advanced solid tumors, often leading to poor patient outcomes. Enhancing the efficacy of radiotherapy through metabolic modulation, particularly targeting lactate metabolism, is a promising strategy to improve treatment responses. This study explores the rapid pharmacodynamic effects of intravenous L-arginine on lactate dynamics in this patient population.
Data Highlights
Group
Median ΔLac_T3
p-value
Pooled L-arginine
-1.09
0.0012
30 g L-arginine
63.5% reduction
<0.001
Key Findings
Intravenous L-arginine significantly reduced lactate levels in brain metastases compared to controls.
The 30 g dose of L-arginine resulted in the most substantial lactate reduction, with a peak effect at 30 minutes.
No treatment-related adverse events were reported within 24 hours post-infusion.
The study supports the hypothesis that L-arginine may enhance radiotherapy efficacy through metabolic modulation.
Future phase II trials are warranted to validate the clinical benefits of L-arginine in this context.
Clinical Implications
The findings suggest that intravenous L-arginine could be a viable adjunct to radiotherapy for patients with brain metastases, potentially improving treatment outcomes. Clinicians should consider the timing and dosing of L-arginine in future treatment protocols to optimize therapeutic efficacy.
Conclusion
This proof-of-concept study highlights the rapid and safe metabolic effects of intravenous L-arginine in brain metastases, paving the way for further investigation into its role as a radiosensitizer in clinical practice.
